PT  - JOURNAL ARTICLE
AU  - Alexander Raskin
AU  - Rohit S. Loomba
TI  - Characteristics of admissions for Kawasaki Disease from 1997 to 2012: Lessons from a national database
AID  - 10.1101/2022.04.30.22274523
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.30.22274523
4099  - http://medrxiv.org/content/early/2022/05/01/2022.04.30.22274523.short
4100  - http://medrxiv.org/content/early/2022/05/01/2022.04.30.22274523.full
AB  - A majority of large epidemiologic studies on Kawasaki Disease have come from Asia. There is paucity of data assessing Kawasaki Disease on a national level in the U.S., particularly in terms of hospitalization co-morbidities and cost. This study set forth to analyze data from the Kids’ Inpatient Database from 1997 to 2012. Data were analyzed for age, race, cardiogenic shock, acute kidney injury, liver failure, acute respiratory distress syndrome, arrhythmia, and congenital heart disease. Additionally, multivariate regression analysis was performed to assess the impact of Kawasaki Disease on coronary artery aneurysms, ECMO, length of stay, cost of stay, and mortality. Asian and Pacific Islander children were disproportionally affected by Kawasaki Disease in the U.S (20.8% of Kawasaki Disease admissions vs 3.3% of all other pediatric hospital admissions, p<0.01). Patients hospitalized for Kawasaki Disease had an increased risk of developing coronary artery aneurysms (OR 2,839, 95%CI 2,2985-3,527) and cardiogenic shock (OR 3.42, 95% CI 2.18-5.37). Patients with Kawasaki disease were less likely to have congenital heart disease (OR 0.62, 95%CI 0.55-0.69), arrhythmia (OR 0.31, 95%CI 0.11-0.84), and acute respiratory distress syndrome (OR 0.29, 95%CI 0.19-0.43). Kawasaki disease patients had shorter hospitalization length of stay by 2.59 days (p <0.01) and decreased cost of stay by $5,513 (p <0.01). Kawasaki Disease had lower mortality when compared to all other admissions (OR 0.03, 95%CI 0.01-0.09). No significant differences were found for ECMO, acute kidney injury, or liver failure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advocate Children's IRB approval waived as deidentified data from the national KIDS dataset used.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are present